

MELAN ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/ Support	STUDY	O R P E E G N	ARM	ACCR. GOAL	TOTAL REGS.	REGS.	REGS.	REGS.	REGS.	REGS.	DATE OF FIRST REG.	# of ACT. INSTs	# of CURR IRBs	
						LAST 12 Month	LAST 6 Month	LAST 3 Month	LAST 30 DAYS	LAST 7 DAYS				
SWOG	S1320-Adv, BRAF mut, Inter v Contin	1	Y 1	Lead-in Continuous Dosing	280	162	57	33	17	5	2	09/19/2014	243	104
						162	57	33	17	5	2			
		2	Y 2	Continuous Dosing	280	64	22	11	7	1	1	09/19/2014		
				3 Intermittent Dosing		64	23	11	4	0	0			
						128	45	22	11	1	1			
	S1404-Melan, Adv, HD-IFN/Ipilimumab vs MK-3475	1	Y 1	Tissue for PD-L1 testing	1378	1302	1024	538	254	94	24	11/10/2015	413	175
						1302	1024	538	254	94	24			
		2	Y 2	FDA approved regimen	1378	605	483	267	126	48	15	11/10/2015		
				3 MK-3475 (Pembrolizumab)		589	474	249	115	40	8			
						1194	957	516	241	88	23			
	S1512-Melan, Adv, Desmoplastic, MK-3475 (pembro)	1	Y 1	MK-3475 (pembrolizumab)	77	1	1	1	0	0	0	02/06/2017	62	26
						1	1	1	0	0	0			
Yes	EA6134-Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T	1	E	Total Registrations		16	9	3	1	0	0	11/03/2015	338	140
						16	9	3	1	0	0			
		2	E	Total Registrations		4	4	1	1	1	0	11/03/2015		
						4	4	1	1	1	0			
	EA6141-Melan, Adv, Nivolumab+Ipi ± Sargmostim	1	E	Total Registrations		36	29	21	15	4	0	03/25/2016	298	120
						36	29	21	15	4	0			
No	E3612-MELAN, Adv Ipilimumab±Bevacizumab	1	E	Total Registrations		5	1	0	0	0	0	02/16/2015	147	56
						5	1	0	0	0	0			

MELAN Open Studies with No Registrations

<u>Study</u>	<u>Registration/Phase</u>	<u>Open Date</u>
S1616 MELAN,, Adv, Ipilimumab ± Nivolumab	1 Randomization	17-Jul-17